Adaptive Biotechnologies president and COO Julie Rubinstein reports sale of $879,088.47 in common shares

ADPT•2026-10-21

Julie Rubinstein sold 35,643 Adaptive Biotechnologies common shares from Oct. 19-21, 2026, after exercising options to acquire the same number at $12.14 per share.

1. Share transactions

Following the transactions, Rubinstein directly held 377,802 common shares and 201,562 stock options.

Sources

Adaptive Biotechnologies president and COO Julie Rubinstein reports sale of $879,088.47 in common shares

Sec

Adaptive Biotechnologies president and COO Julie Rubinstein reports sale of $879,088.47 in common shares

1. Share transactions

Related News

Opaleye Management reports acquisition of $8,001.28 in Grace Therapeutics common shares

Mara Holdings CFO Salman Hassan Khan reports sale of $126,080 in common shares

Professional Diversity Network enters three securities purchase agreements on Oct. 16, 2026

Sources

Adaptive Biotechnologies president and COO Julie Rubinstein reports sale of $879,088.47 in common shares

Supernus Pharmaceuticals says FDA grants seven years of orphan-drug exclusivity for Onapgo

Tesla cuts spending before potential SpaceX deal as Musk bets on AI and robots